Peripheral blood CD4$^+$CCR6$^+$ compartment differentiates HIV-1 infected or seropositive elite controllers from long-term successfully treated individuals

Sara Svensson Akusjärvi$^1$, Shuba Krishnan$^1$, Bianca B. Jütte$^2$, Anoop T. Ambikan$^1$, Soham Gupta$^1$, Jimmy Esneider Rodriguez$^3$, Ákos Végvári$^3$, Maike Sperk$^1$, Piotr Nowak$^4$, Jan Vesterbacka$^4$, J. Peter Svensson$^2$, Anders Sönnerborg$^{1,4}$ & Ujjwal Neogi$^{1,5,6}$

HIV-1 infection induces a chronic inflammatory environment not restored by suppressive antiretroviral therapy (ART). As of today, the effect of viral suppression and immune reconstitution in people living with HIV-1 (PLWH) has been well described but not completely understood. Herein, we show how PLWH who naturally control the virus (PLWHEC) have a reduced proportion of CD4$^+$CCR6$^+$ and CD8$^+$CCR6$^+$ cells compared to PLWH on suppressive ART (PLWHART) and HIV-1 negative controls (HC). Expression of CCR2 was reduced on both CD4$^+$, CD8$^+$ and classical monocytes in PLWHEC compared to PLWHART and HC. Longer suppressive therapy, measured in the same patients, decreased number of cells expressing CCR2 on all monocytic cell populations while expression on CD8$^+$ T cells increased. Furthermore, the CD4$^+$CCR6$^+$/CCR6$^-$ cells exhibited a unique proteomic profile with a modulated energy metabolism in PLWHEC compared to PLWHART independent of CCR6 status. The CD4$^+$CCR6$^+$ cells also showed an enrichment in proteins involved in apoptosis and p53 signalling in PLWHEC compared to PLWHART, indicative of increased sensitivity towards cell death mechanisms. Collectively, this data shows how PLWHEC have a unique chemokine receptor profile that may aid in facilitating natural control of HIV-1 infection.
Efficient antiretroviral therapy (ART) suppresses human immunodeficiency virus type 1 (HIV-1) replication to below the detection level of sensitive HIV RNA assays. Still, HIV-1 persists for decades despite efficient ART in presumably latently infected cells, making up the so-called latent viral reservoir. This reservoir resides in subtypes of memory T cells and cells from monocytic lineages, but also in some functional and naïve T cell subsets. Eradication of latently infected cells, i.e., a sterilizing cure, has proven to be a major hurdle due to several factors such as heterogeneity in mechanisms governing latency and integration sites into the host genome. Over the course of suppressive ART, persisting HIV-1 sustained by low levels of viral replication, homoeostatic proliferation, and cell-to-cell transmission, is a driver of chronic immune activation in the host. In HIV-1 infection, chemokine receptors are essential coreceptors needed for HIV-1 entry into the cell where the CC chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) are the main co-receptors used for HIV-1 entry, but alternative receptors such as CCR3 may play a role for macrophage-tropic viral strains. T cells expressing the chemokine receptor CCR6 are also overrepresented amongst cell types infected by HIV-1. Furthermore, CD4+CCR6+ and CD4+CCR2+CCR5+ cells have been proposed to contribute to the HIV-1 reservoir.

Alterations in chemokine receptor expression and chemokine levels modulate the activity of the immune response and inflammatory levels during HIV-1 infection. In people living with HIV-1 (PLWH) on suppressive ART, these aberrations may contribute to (i) higher risk of age-associated co-morbidities together with elevated immune activation, (ii) microbiome dysbiosis leading to microbial translocation and (iii) dysregulated immune cell activation and function. Consequently, HIV-1 pathogenesis and immune dysfunction promote chronic immune activation. This results in a vicious cycle as immune activation likely drives HIV-1 disease progression and inflammation, defined as an age-related increase of inflammatory markers, that could possibly lead to earlier onset of age-related diseases. In our earlier study on a small group of 10 PLWH on ART for two decades, we reported normalisation of most of the plasma pro-inflammatory cytokines and chemokines to the level of HIV-negative controls. Therefore, although there are several studies on immune reconstitution and viral suppression during short-term ART, the long-term effect of ART on the immune system is not known.

Eradication of latently infected cells, i.e., a sterilising cure, has proven to be a major hurdle. An alternative approach is a functional cure aimed at suppressing viral replication without ART. A model for functional cure studies is elite controllers (herein PLWHEC). PLWHEC constitute a small fraction (<0.5%) of HIV-1+ individuals able to naturally control viral replication in the absence of ART. However, there is a population-based heterogeneity of how these individuals suppress viral replication which is likely caused by several factors such as viral and host genetic factors, variability of integration site in the human genome, and variation in the host response such as immunological factors. In terms of immune cell activation, studies have shown how PLWHEC maintain lower levels of inflammatory markers compared to PLWH who progress in their disease. However, as no consensus exists on how the PLWHEC phenotype is maintained, further studies comparing variability of immune function between PLWHEC and PLWH on suppressive ART (herein PLWHART) are required to understand the mechanisms of natural control of HIV-1.

In our recent study, we hypothesised that an altered CCR6/CCL20 chemokine axis and CCR2-CCL7-CCL2 signalling may play a protective role in the PLWHEC phenotype. We identified a downregulation of CCR2 and CCR6 receptors on CD4+ and CD8+ lymphocytes and higher plasma abundance of CCL4, CCL7 and CCL20 in PLWHEC compared to the HIV-1-negative controls. This can provide natural resistance to HIV-1 infection although the expression profile during long-term suppressive ART is not known. In the present study, we extended our analysis to evaluate the expression profile dynamics of key chemokine receptors CCR2, CCR3, CCR5 and CCR6 in PLWHART. We also compared the proportion of integrated HIV-1 between PLWHEC and PLWHART.

In the present study, we extended our analysis to evaluate the expression profile dynamics of key chemokine receptors CCR2, CCR3, CCR5 and CCR6 in PLWHART.

**Results**

PLWHEC have reduced populations of CD4+CCR6+ and CD4+CCR2+ T lymphocytes compared to successfully long-term treated patients. Herein, we wanted to evaluate if there are any differences in the expression profile of some key chemokine receptors between PLWH with natural control of the virus and those on ART. Therefore, we investigated the expression levels of CCR2, CCR3, CCR5 and CCR6 in peripheral blood mononuclear cells (PBMCs) from PLWHEC (n = 14), PLWHART (n = 54) and HIV-negative individuals (HC, n = 18) by flow cytometry (Supplementary Fig. 1). The clinical and demographic data are presented in Table 1 and Supplementary Table 1. All the PLWHART were successfully treated at the time of sample collection and plasma viral load was below the detection level (<40 copies/mL). Initial discrimination between CD4+ T cells (CD3+CD4+) and CD8+ T cells (CD3+CD8+) showed that both PLWHEC and PLWHART exhibited a reduced proportion of CD4+ T cells and elevated proportion of CD8+ T cells compared to HC (Fig. 1a).

Singlet receptor expression in PLWHEC showed a distinct profile compared to both PLWHART and HC (Fig. 1b). Expression of CCR2 and CCR6 was reduced on both CD4+ and CD8+ T cells together with a decreased proportion of CD8+CCR2+, CD4+CCR6+ and CD8+CCR6+ in PLWHEC compared to both PLWHART and HC (Fig. 1c, d). The expression levels of CCR2 were also reduced on CD8+ T cells in PLWHART compared to HC, as well as the proportion of CD8+CCR6+ cells (Fig. 1c, d). Even as the total frequency of CD4+CCR3+ was low in all three groups, the expression of CCR3 was high in both PLWHEC and PLWHART compared to HC (Supplementary Fig. 2a). Furthermore, expression levels of CCR5 were lower on CD4+ T cells in PLWHEC compared to HC while CCR2+CCR6+ in PLWHART showed no differences were detected on CD4+ T cells. Collectively, these data show how PLWHEC have a unique expression profile of CCR2 and CCR6 while the expression signature of CCR3 is more similar to PLWHART on lymphocytic cells (Fig. 1e). Continuing, co-expression analysis on CD4+ cells showed that CCR2+CCR5+CCR6+ and CCR2+CCR6+ and CCR5+CCR6+ were reduced in PLWHEC compared to both PLWHART and HC, while no differences were detected between PLWHART and HC (Fig. 1f). Furthermore, single receptor expression of CCR2 was reduced in PLWHEC compared to PLWHART and CCR6 expression was reduced in PLWHEC compared to both PLWHART and HC (Fig. 1f). Within the CD8+ T cell population, co-receptor expression of CCR2+CCR5+CCR6+ was reduced in both PLWHART and PLWHEC compared to HC while CCR2+CCR5+ was reduced in PLWHEC compared to HC and PLWHART (Fig. 1g). Single receptor expression analysis also showed that CCR5 was increased in PLWHEC compared to HC and CCR6 expression decreased in PLWHEC compared to both HC and
PLWH\textsubscript{ART} (Fig. 1g). As the major differences were detected on CCR2 and CCR6 expression, we measured the levels of their ligands, namely monocyte chemoattractant protein 1, MCP1 (CCL2) and macrophage inflammatory protein 3, MIP-3 (CCL20), respectively, in plasma from PLWH\textsubscript{ART} (Fig. 2c). The major difference was a reduced expression of CCR2 in PLWHEC compared to PLWH\textsubscript{ART} and HC, while the frequency of CM-CCR3 and CCR6 was low on all three monocytic cell subsets (Fig. 2c). The major difference was a reduced expression of CCR2 on CM and IM in PLWH\textsubscript{EC} compared to HC and on CM compared to PLWH\textsubscript{ART} (Fig. 2d). In PLWH\textsubscript{ART}, both the frequency of IM-CCR2\textsuperscript{+} cells and expression of CCR2 on IM cells were reduced compared to HC (Fig. 2d). Although the proportion of CM-CCR6\textsuperscript{+} cells was decreased in PLWH\textsubscript{EC} compared to PLWH\textsubscript{ART}, CCR6 expression was increased in PLWH\textsubscript{EC} compared to HC and PLWH\textsubscript{ART}, while PLWH\textsubscript{ART} showed reduced expression compared to HC (Supplementary Fig. 3b). Furthermore, NCM-CCR6\textsuperscript{+} cells were lower in PLWH\textsubscript{EC} compared to PLWH\textsubscript{ART} and HC, and the frequency of CM-CCR3\textsuperscript{+} cells was decreased in PLWH\textsubscript{EC} compared to PLWH\textsubscript{ART} (Supplementary Fig. 3b, c). The receptor expression of CCR5 was reduced on IM in PLWH\textsubscript{ART} compared to HC and on NCM in PLWH\textsubscript{EC} compared to both PLWH\textsubscript{ART} and HC (Supplementary Fig. 3d). This data indicates that the main difference in the monocytic cell subset is a reduced expression of CCR2 in PLWH\textsubscript{EC} compared to the other groups (Fig. 2e). The IM were the only monocytic cell population which exhibited differences in co-receptor expression. For these cells, the largest variation was a reduction of CCR2\textsuperscript{+}CCR5\textsuperscript{+} expressing cells in both PLWH\textsubscript{EC} and PLWH\textsubscript{ART} compared to HC. An increase in cells lacking all four receptors was found in both PLWH\textsubscript{EC} and PLWH\textsubscript{ART} compared to HC (Fig. 2f). Furthermore, PLWH\textsubscript{ART} exhibited reduced numbers of cells expressing only CCR2 compared to HC (Fig. 2f). Collectively, this data shows that the largest variation occurred on IM where PLWH\textsubscript{ART} and PLWH\textsubscript{EC} showed a similar trend compared to HC.

**Table 1 Patient characteristics.**

| Parameter | PLWH\textsubscript{EC} | PLWH\textsubscript{ART} | HC | \(P\)-values |
|-----------|------------------------|------------------------|----|--------------|
| N         | 14                     | 54                     | 18 | ND           |
| Gender: Female, N (%) | 7 (50)                | 19 (35)                | 9 (50) | ND |
| Ethnicity, N (%) |                      |                        |    |              |
| Black     | 9 (64.2)               | 21 (38.8)              | 5 (27.7) | ND |
| Asian     | -                      | 2 (3.7)                | -  |              |
| Caucasian | 4 (28.6)               | 31 (57.4)              | 13 (72.2) |              |
| Hispanic  | 1 (7.1)                | -                      | -  |              |
| Age in years, mean (SD) | 46 (10.5)            | 50 (9.5)               | 47 (9) | 0.2704* |
| CD4\textsuperscript{+} T cell count (cells/µL); median (IQR) | 680 (570-1060)       | 660 (485-795) | NA | 0.5012* |
| CD8\textsuperscript{+} T cell count (cells/µL); median (IQR) | 900 (540-1330)       | 600 (415-950) | NA | 0.0974* |
| CD4:CD8 ratio; median (IQR) | 1 (0.44-1.18)       | 1 (0.7-1.45)           | NA | 0.3295* |
| Duration of treatment in years; median (IQR) | NA                    | 8 (6.75-19)            | NA |              |
| Duration of suppressive treatment in years; median (IQR) | NA                    | 8 (7-15)               | NA |              |
| Years HIV positive; median (IQR) | 7 (4.5-11.7)        | 12.5 (9-20)            | NA | 0.0012* |
| HIV RNA load; <40 copies/mL (IQR) |                      | <40 copies/mL | NA |              |
| Treatment regimen, N (%) |                      |                        |    |              |
| 3rd drug.  |                        |                        |    |              |
| Boosted PI |                        |                        |    |              |
| INSTI     | 2 (3.7)                | 30 (55.5)              | NA |              |
| NNRTI     | NA                    | 21 (38.8)              | NA |              |
| 1st drug.  |                        |                        |    |              |
| ABC       | 34 (62.9)              | 16 (29.6)              | NA |              |
| TAF/TDF   | 4 (7.4)                | 16 (29.6)              | NA |              |
| Other     | 4 (7.4)                | 16 (29.6)              | NA |              |
| Initiation of treatment |            |                        |    |              |
| CD4\textsuperscript{+} T cell count at treatment initiation (cells/µL); median (IQR) | NA | 351 (167.5-522.5) | NA |              |
| Viral Load at treatment initiation; Log\textsubscript{10} copies/mL (IQR) | NA | 4.79 (4.06-5.44) | NA |              |

\(\text{ABC}\) abcavir, IQR interquartile range, N number, NA not applicable, ND not done, PI protease inhibitor, INSTI integrase strand transfer inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, SD standard deviation, TAF tenofovir alafenamide, TDF tenofovir disoproxil.

*One-way ANOVA.

* Mann-Whitney test.

CCR2 expression is reduced in PLWH\textsubscript{EC} compared to PLWH\textsubscript{ART} on monocytic cell populations. In HIV-1 infection there is a chronic activation of monocytes contributing to organ-specific inflammatory events that are poorly understood in virologically suppressed patients. Our group and others have previously shown persistent low-level inflammation in PLWH\textsubscript{EC}\textsuperscript{24–26}. Furthermore, chemokine receptors like CCR2 and CCR5 play a major role in inflammatory trafficking of monocytes\textsuperscript{27}. Therefore, we determined the CCR2, CCR3, CCR5 and CCR6 receptor expression in monocytic cell populations; classical (CM, CD14\textsuperscript{+}CD16\textsuperscript{−}), intermediate (IM, CD14\textsuperscript{+}CD16\textsuperscript{+}) and non-classical (NCM, CD14\textsuperscript{−}CD16\textsuperscript{+}). Herein, PLWH\textsubscript{EC} exhibited reduced numbers of CM compared to HC and elevated levels of IM compared to both HC and PLWH\textsubscript{ART} (Fig. 2a, b and Supplementary Fig. 3a). Generally, the receptor expression of CCR3 and CCR6 was low on all three monocytic cell subsets (Fig. 2c). The major difference was a reduced expression of CCR2 on CM and IM in PLWH\textsubscript{EC} compared to HC and on CM compared to PLWH\textsubscript{ART} (Fig. 2d). In PLWH\textsubscript{ART}, both the frequency of IM-CCR2\textsuperscript{+} cells and expression of CCR2 on IM cells were reduced compared to HC (Fig. 2d). Although the proportion of CM-CCR6\textsuperscript{+} cells was decreased in PLWH\textsubscript{EC} compared to PLWH\textsubscript{ART}, CCR6 expression was increased in PLWH\textsubscript{EC} compared to HC and PLWH\textsubscript{ART}, while PLWH\textsubscript{ART} showed reduced expression compared to HC (Supplementary Fig. 3b). Furthermore, NCM-CCR6\textsuperscript{+} cells were lower in PLWH\textsubscript{EC} compared to PLWH\textsubscript{ART} and HC, and the frequency of CM-CCR3\textsuperscript{+} cells was decreased in PLWH\textsubscript{EC} compared to PLWH\textsubscript{ART} (Supplementary Fig. 3b, c). The receptor expression of CCR5 was reduced on IM in PLWH\textsubscript{ART} compared to HC and on NCM in PLWH\textsubscript{EC} compared to both PLWH\textsubscript{ART} and HC (Supplementary Fig. 3d). This data indicates that the main difference in the monocytic cell subset is a reduced expression of CCR2 in PLWH\textsubscript{EC} compared to the other groups (Fig. 2e). The IM were the only monocytic cell population which exhibited differences in co-receptor expression. For these cells, the largest variation was a reduction of CCR2\textsuperscript{+}CCR5\textsuperscript{+} expressing cells in both PLWH\textsubscript{EC} and PLWH\textsubscript{ART} compared to HC. An increase in cells lacking all four receptors was found in both PLWH\textsubscript{EC} and PLWH\textsubscript{ART} compared to HC (Fig. 2f). Furthermore, PLWH\textsubscript{ART} exhibited reduced numbers of cells expressing only CCR2 compared to HC (Fig. 2f). Collectively, this data shows that the largest variation occurred on IM where PLWH\textsubscript{ART} and PLWH\textsubscript{EC} showed a similar trend compared to HC.
Longer suppressive therapy reduces expression of CCR2 on monocytes. The chronic inflammatory condition due to HIV-1 persistence and an activated immune response persists during suppressive ART. Therefore, to evaluate if longer treatment duration affects the receptor expression, we included longitudinal samples (timepoint 1 (T1) $n = 10$ and timepoint 2 (T2) $n = 10$) where the same patients were followed-up after 3 years of additional suppressive therapy (clinical parameters can be viewed in Supplementary Table 2). Treatment duration did not affect frequencies of CD4$^+$, CD8$^+$ T cells or monocytic cell populations (Supplementary Fig. 4a, b). For the detected receptor expressions, most of the differences were detected in the monocytic cell populations while no significant variations were seen on CD4$^+$ T cells (Fig. 3a). Longer treatment duration increased the
Fig. 1 CCR2 and CCR6 are specifically depleted from T lymphocytes in PLWH. Receptor expression on CD4+ and CD8+ T lymphocytes from PLWH (n = 14), PLWHART (n = 54) and HC (n = 18). a Frequencies of CD4+ T cells and CD8+ T cells in total peripheral blood mononuclear cells derived from CD3+ cells. b Bubble chart representing receptor expression of CCR2, CCR3, CCR5 and CCR6 on CD4+ and CD8+ T cells. Size of the bubble corresponds to percentage-positive cells while colour represents the median fluorescence intensity (MFI). c CCR2 receptor expression on CD4+ and CD8+ T cells (% cells and MFI). d CCR6 receptor expression on CD4+ and CD8+ T cells (% cells and MFI). e t-SNE plots showing receptor expression distribution on CD4+ and CD8+ T cells. f Co-receptor expression of CCR2, CCR3, CCR5 and CCR6 on CD4+ T cells. g Co-receptor expression of CCR2, CCR3, CCR5, and CCR6 on CD8+ T cells. c, d Contour plots show a representing sample from PLWH, PLWHART and HC corresponding to the median % of cells within each group. a, c, d, f, g Statistical significance was determined using two-tailed Mann-Whitney U-test (significance level p < 0.05, with *<0.05, **<0.001) and represented as pie charts or with median using 95% CI.

Fig. 2 CCR2 is depleted from intermediate monocytes of PLWH. Receptor expression on monocytic subpopulations (classical monocytes (CM); CD14+CD16−, intermediate monocytes (IM) CD14−CD16+ and non-classical monocytes (NCM); CD14−CD16+) in PLWH (n = 14), PLWHART (n = 54) and HC (n = 18). a, b Percentages of CM (a) and IM (b) from CD3+ cells in peripheral blood mononuclear cells. c Bubble chart representing receptor expression of CCR2, CCR3, CCR5 and CCR6 on CM, IM and NCM. Size of the bubble corresponds to percentage-positive cells while colour represents the median fluorescent intensity (MFI). d CCR2 receptor expression on CM and IM (% cells and MFI). e t-SNE plots showing receptor expression distribution of CCR2, CCR3, CCR5 and CCR6 on IM, IM and NCM. f Co-receptor expression of CCR2, CCR3, CCR5 and CCR6 on IM. f Contour plot shows a representing sample from PLWH, PLWHART and HC corresponding to the median % of cells within each group. a, b, f Statistical significance was determined using two-tailed Mann-Whitney U-test (significance level p < 0.05, with *<0.05, **<0.001) and represented as pie charts or with median using 95% CI.
Fig. 3 In time, CCR2 and CCR6 increase on CD8 cells while CCR2 decreases on monocytes in PLWH ART. Receptor expression of longitudinal data on lymphocytes and monocytes at arbitrary timepoint 1 (T1) (n = 10) and three years later at timepoint 2 (T2) (n = 10) from total peripheral blood mononuclear cells. a Bubble chart representing receptor expression of CCR2, CCR3, CCR5 and CCR6 on CD4\(^{+}\) and CD8\(^{+}\) T cells together with classical (CM; CD14\(^{+}\)CD16\(^{-}\)), intermediate (IM; CD14\(^{+}\)CD16\(^{+}\)), and non-classical (NCM; CD14\(^{-}\)CD16\(^{+}\)) monocytes. Size of the bubble corresponds to percentage-positive cells while colour represents the median fluorescent intensity (MFI). b, c Receptor expression of CCR2 on CD4\(^{+}\), CD8\(^{+}\), CM, IM and NCM. d MFI of CCR2 on CD4\(^{+}\), CD8\(^{+}\), CM, IM and NCM. e, f Receptor expression of CCR3 on CD8\(^{+}\) T cells. g MFI of CCR3 on CD8\(^{+}\) T cells. h, i Receptor expression of CCR3 on IM. j MFI of CCR3 on IM. k, l Receptor expression of CCR5 on IM. m MFI of CCR5 on IM. n, o Co-receptor expression of CCR2, CCR3, CCR5 and CCR6 on CD8\(^{+}\) T cells (n) and IM (o). b, e, h, k Contour plot shows a representing sample from T1 and T2 corresponding to the median % of cells within each group. c, d, f, g, i, j, l-o Statistical significance was determined using two-tailed Wilcoxon matched-pairs signed-rank test (significance level \(p < 0.05\), with *<0.05, **<0.001) and represented as paired before and after plot, median using 95% CI or as pie charts.
frequency of CD8+CCR2+ cells, while all three monocytic cell populations exhibited reduced proportions of cells expressing CCR2 in T2 (Fig. 3b, c). Following a similar trend, CCR2 expression was increased on CD8+ T cells and IM exhibited reduced expression of CCR2 in T2 while CM and NCM showed no difference (Fig. 3d). The proportion of CD8+CCR6+ cells was increased in T2, without showing any significant effect on CCR6 expression levels (Fig. 3e–g). Furthermore, the proportions of IM-CCR3+ and IM-CCR5+ cells decreased over time while only expression levels of CCR5 decreased in T2 (Fig. 3h–m). Investigations of co-receptor expression on the lymphocytic cell populations showed that the only difference was an increase in CCR2+CCR5+ in T2 on CD8+ T cells (Fig. 3n). Within the monocytic cell populations, the only differences of co-expression of the receptors were seen on IM where T2 exhibited higher percentage of cells negative for all four receptors while CCR2+, CCR2+CCR3+, and CCR2+CCR5+ were decreased in T2 (Fig. 3o). Conclusively, the effect induced by longer suppressive treatment mainly reduces expression levels of these chemokine receptors on IM.

The HIV-1 reservoir is lower in PLWH_EC compared to PLWH_ART. To evaluate the proportion of HIV-1 infected cells in our cohort, we quantified total HIV-1 DNA in the PLWH_EC (n = 14) and PLWH_ART (n = 54). Herein, we observed a higher level of total HIV-1 DNA in PLWH_ART compared to PLWH_EC (Fig. 4a) despite a median of eight years of successful treatment. No significant difference was observed between long-term ART (lnART; >10 yrs (median 20 yrs, Interquartile range (IQR); 18–22.75), n = 20) and short-term ART (sART; <10 yrs (median 7 yrs, IQR; 6–8), n = 34) nor was the reservoir affected by longer suppressive treatment between T1 and T2 within the same individuals (Fig. 4b, c). This data indicates that after the initial two phases of HIV DNA decline the size of the reservoir is not affected during successful suppressive ART. However, PLWH_EC exhibited reduced proportions of HIV-1 infected cells presumably due to their natural control of HIV-1. Next, to evaluate the proportion of integrated HIV-1 that was intact/defective, we employed the intact provirus DNA assay (IPDA) together with quantification of the 5′LTR and 2-LTR circles on the genomic DNA from PBMCs. A significant increase of 3′ deletion/hypermutation was detected in PLWH_ART compared to PLWH_EC, but no significant differences in intact provirus, 5′LTR or 2-LTR circles between the two groups (Fig. 4d). Moreover, percentages of intact provirus out of total HIV-1 DNA did not differ between the groups (Fig. 4e). The CCL20 ligand for CCR6 can facilitate nuclear integration of HIV-1 by remodelling the actin cytoskeleton, but also directly inhibits infection in the female reproductive tract. Therefore, to evaluate if the ligands for CCR2 and CCR6 might have an effect on the HIV-1 reservoir we performed correlation analysis between plasma levels of CCL20 and the HIV-1 reservoir. No significant correlation between HIV-1 DNA and CCL20 plasma levels was revealed in

Fig. 4 The HIV-1 reservoir in PLWH_EC is distinct from PLWH_ART. a Quantified total HIV-1 DNA in peripheral blood mononuclear cells from PLWH_EC (n = 14) and PLWH_ART (n = 54). b Total HIV-1 DNA in short-term ART (sART; <10 yrs, n = 34) compared to long-term ART (lnART; >10 yrs, n = 20) in people living with HIV-1 on suppressive therapy. c Total HIV-1 DNA in longitudinal data from HIV-1 infected individuals (timepoint 1 (T1), n = 10 and timepoint 2 (T2), n = 10). d Box and Whisker plot show the distribution of integrated HIV-1 DNA copies per 10⁶ PBMCs in PLWH_ART (n = 54) and PLWH_EC (n = 14) with whiskers representing the 10–90 percentile. The median is represented by the line inside the box. The dotted line marks the background represented by HC samples. e Percentage of intact provirus out of total HIV-1 DNA detected. Statistical significance was determined using two-tailed Mann-Whitney U-test (significance level p < 0.05, with “<0.05, **<0.001”) and represented as median using 95% CI. All individual samples were run in technical duplicates.
either PLWHEC or PLWHART (Supplementary Fig. 5a). For CCL2, a negative correlation was detected in PLWHEC but not in PLWHART (Supplementary Fig. 5b). Collectively, this data indicates that although PLWHART have higher proportion of infected cells compared to PLWHEC, a larger fraction of the integrated HIV-1 carries hypermutations or 3′deletions within the viral genome. Furthermore, the frequency of intact provirus out of total HIV-1 DNA is low in both PLWHEC and PLWHART.

Altered metabolic pathways in CD4+CCR6+ cells are characterised by an upregulation in p53 signalling and apoptosis in PLWHART. The subpopulation of CD4+CCR6+ cells has been described as more permissive towards HIV-1 and targets for productive infection.23-25 To further characterise the CD4+ T cells that express or lack the CCR6 receptor we sorted out these cell populations using fluorescence-activated cell sorting (FACS) from HC (n = 3), PLWHEC (n = 6) and PLWHART (n = 6) (Fig. 5a). The PLWHART samples were selected from PLWH on long-term suppressive ART (median 30 year; IQC: 17.5–22.25). First, as the HIV-1 reservoir has been proposed to reside in CD4+CCR6+ T cells, we measured the amount of integrated HIV-1 in PLWHEC (n = 5) and PLWHART (n = 3). However, the variation within the data and the small sample size made the comparison inconclusive (Supplementary Fig. 6a). To evaluate the specific proteomic profile of CD4+CCR6+ and CD4+CCR6− cell populations we isolated these cell populations by FACS (15,000–30,000 cells) and performed mass spectrometry-based proteomics using a quantitative tandem mass tags (TMT) labeling approach. Due to low protein detection by mass spectrometry four PLWHEC samples, two samples out of each of the CCR6+ and CCR6− cell populations were excluded from the analysis. The principal component analysis (PCA) identified heterogeneity among the samples (Supplementary Fig. 6b). Differential expression analysis was unable to find statistically significant regulated proteins due to heterogeneity among samples and low sample size. Therefore, functional analysis was performed using a consensus scoring approach based on multiple protein set analysis (PSA) run by incorporating the directionality of protein abundance. Using the group-specific consensus scores (PLWHEC vs PLWHART) and directionality classes, we identified distinct upregulation of oxidative phosphorylation (OXPHOS) (adj p < 0.05) and interferon-α response (adj p < 0.05) and distinct downregulation of glycolysis (adj p < 0.05) in both CD4+CCR6+ and CD4+CCR6− cells while using the MSigDB hallmark gene set (Fig. 5b). Similarly, the KEGG gene set also identified a distinct upregulation of OXPHOS (adj p < 0.1), and a distinct down-regulation of other pathways of amino acid and carbohydrate metabolism (Supplementary Fig. 6c). This data indicates that the metabolic trade-off of increased OXPHOS and reduced glycolysis is elevated in PLWHEC compared to PLWHART (Fig. 5c). The relative abundance of the OXPHOS proteins was higher in PLWHEC compared to HC while lower in PLWHART compared to HC (Supplementary Fig. 7a, b). Interestingly, only p53 signalling and apoptosis were distinctly upregulated in CD4+CCR6+ (adj p < 0.05) (Fig. 5b) and both pathways had unique features in PLWHEC (Fig. 5d, e). The majority of the PLWHART clustered together. There were two downregulated proteins in PLWHEC (ISCU and LDHB) that were common between OXPHOS and p53 signalling. Furthermore, four proteins (CASP7, VDAC2, RHOT2 and GPX4) were common between OXPHOS and apoptosis, while seven proteins (FAS, tap1, FDXR, TXNIP, CASP1, APP and HMOX1) were common between p53 signalling and apoptosis among the proteins upregulated in PLWHEC compared to PLWHART (Fig. 5f). Taken together, this data shows how the CD4+CCR6+ cell population have a unique profile in PLWHEC. The co-regulation of OXPHOS, p53 signalling and apoptosis may be a contributing factor to control HIV-1 infection.

Discussion

In our study, a unique cell type expression profile of CCR2 and CCR6 was identified in PLWHEC, while PLWHART exhibited an expression profile more like HC. CCR6+ cells were thus decreased on both CD4+ and CD8+ T cells in PLWHEC but not in PLWHART. Furthermore, the CD4+ T cells exhibited a protein profile of modulated metabolic activity towards OXPHOS, and reduced protein levels involved in glycolysis in PLWHART irrespective of CCR6 status. Collectively, as CD4+CCR6+ cells have been reported to be highly permissive to HIV-131,32, and substantial contributors to the HIV-1 reservoir, low levels of CD4+CCR6+ cells, metabolic modulation, and enrichment of proteins involved in cell death, could potentially contribute to natural control of HIV-1.

Within the CD4+ T cell subpopulation, CCR6 expression is a marker of some memory T cells subsets, namely Th17 cells, natural killer T (NKT) cells, and γδ T cells.33 Of these cell populations, the Th17 cells promote a strong pro-inflammatory response and are drivers of chronic inflammation and autoimmune diseases.34,35 Earlier studies have shown how memory CD4+CCR6+ T cells express a Th17 lineage profile and high susceptibility towards HIV-1.36 In our cohort, the proportion of CCR6+ cells was reduced in PLWHEC compared to both PLWHART and HC. CCR6 is also a homing marker for gut-associated lymphoid tissue (GALT).37 Therefore, the causative factor of reduced CD4+CCR6+ cells in peripheral blood in PLWHEC could be tissue residency in GALT to a higher extent than in PLWHART. Although initiation of ART restores the intestinal CD4+ T cell compartments, the severe depletion induced during the early stages of infection cannot be fully recovered, which contributes to exacerbation of HIV-1 through microbial translocation and hyperactivation of the immune system.39-41 Collectively, an increased gut homing potential of CCCR6+ cells in PLWHEC could help to restore the imbalance of CD4+ T cells in GALT and reduce systemic chronic inflammation among these patients.

We have earlier shown that low expression of CCR6 and high levels of its ligand, CCL20, may result in low levels of inflammation in PLWHEC.25 Herein, we detected increased plasma levels of CCL20 in PLWH, independent of HIV-1 status compared to HC, confirming earlier observations.42 CCL20 has previously been described to have an effect on the infection steps of HIV-1 and migration/function of immune cells33. However, we did not see any difference in CCL20 levels between PLWHEC and PLWHART. Therefore, most likely it is the CD4+CCR6+ cells, rather than levels of CCL20, that in PLWHEC could contribute to natural control of HIV-1.

Furthermore, CD4+CCR6+ and CD8+CCR6+ cells decline in untreated patients with HIV-143 since the CCR6+ cells are more susceptible towards apoptosis and therefore involved in the depletion of memory T cells. However, we did not detect any alterations in CD4+CCR6+ compartments in PLWHART compared to HC, although for CD8+CCR6+ cells there was a reduction in both patient groups. We identified the CD4+CCR6+ cells as having increased proteins involved in apoptosis and p53 signalling in PLWHEC indicating an increased sensitivity towards apoptosis, possibly as a result of HIV-1 proteins, activation-induced cell death or induced expression of death receptors, e.g., Fas and TRAIL-R1/TRAIL-R1.44 Since these cells are not restored in the GALT during ART, it can be postulated that the CD4+CCR6+ cell population is a major target for HIV-1 infection.
Fig. 5 CD4⁺ CCR6⁺ are enriched in proteins from p53 and apoptosis signalling in PLWHEC compared to PLWHART. Characteristics of CD4⁺CCR6⁺ and CD4⁺CCR6⁻ cell populations isolated by FACS from PLWHEC (n = 4), PLWHART (n = 6) and HC (n = 3). a Gating strategy for isolation of CD4⁺CCR6⁺ and CD4⁺CCR6⁻ cell populations from total peripheral blood mononuclear cells, exhibited by an HC sample. b Heatmap representation of significant pathways found deregulated in CD4⁺CCR6⁺ PLWHEC compared to CD4⁺CCR6⁺ PLWHART and in CD4⁺CCR6⁻ PLWHEC compared to CD4⁺CCR6⁻ PLWHART using MSigDBv. Colour gradient corresponds to the negative log scaled adjusted p-values. Each column represents p-values of various directionality classes, calculated for the pathways. Non-directional p-values are calculated based on gene-level statistics regardless of the direction of expression. Mixed directional up and mixed directional down p-values are calculated using the subset of the gene statistics that are upregulated and downregulated, respectively. Distinct directional up and distinct directional down p-values are calculated from gene statistics with expression direction. c Schematic representation of metabolic trade-off between OXPHOS and glycolysis detected in the cells. d, e Heatmap representation of proteins part of apoptosis (d) and p53 pathway (e). Colour gradient corresponds to the z-score scaled normalized expression values. Column annotation represents the cohorts and row annotation visualizes the log2 transformed fold change values in each of the differential expression analysis of PLWHART compared with HC, PLWHART compared with HC and PLWHEC compared with PLWHART. f Network visualization of significant pathways enriched in CD4⁺CCR6⁺ PLWHEC compared to CD4⁺CCR6⁺ PLWHART. Each edge represents association of the protein with the corresponding pathways. Circular nodes denote proteins and square-shaped nodes are pathways. Red colour gradient and green colour gradient represent upregulation and downregulation of the proteins in CD4⁺CCR6⁺ PLWHEC compared to CD4⁺CCR6⁺ PLWHART.
infection in PLWH contributes to the inflammatory environment in both GALT and peripheral blood. In PLWHc, these cells may be more susceptible towards apoptosis, possibly through expression of pro-apoptotic HIV-1 proteins during infection or reactivation from latency. Furthermore, p53 is a tumour suppressor gene that during HIV-1 infection is activated by both α and β stimulation of immune cells. Activity of p53 can interfere with HIV-1 replication by inhibiting reverse transcription of the virus and suppressing the activity of the transactivator tat, needed for viral transcription. Therefore, an enrichment of p53 signalling in PLWHc could contribute to natural control of HIV-1 infection in CD4+CCR6+ T cells by reducing replication of HIV-1 and inducing apoptosis upon latency reversal. However, the sample size included in this study is relatively small and further studies validating these results are warranted. In addition, PLWHc exhibited an enrichment of proteins involved in OXPHOS together with decreased number of proteins involved in glycolysis, irrespective of CCR6 expression. Increased glycolysis is a hallmark for T cell activation but also upregulated during HIV-1 infection for cells to sustain the energy-demanding process of viral reproduction. Generally, activation of a T cell causes a shift from OXPHOS to aerobic glycolysis in a similar fashion as the metabolic reprogramming occurring during activation from latency. Therefore, the metabolic state of the CD4+ T cell compartment in PLWHc: independently of CCR6 expression indicates a unique proportion of CD4 T cell subsets and metabolic reprogramming.

Persistent HIV-1 is a driver of chronic immune activation and inflammation. In our cohort, PLWHc had a reduced amount of integrated HIV-1 in total PBMCs compared to PLWHART, correlating to earlier observations. On the other hand, treatment duration did not significantly alter the proportion of latently infected cells probably due to the stability of the reservoir during long-term ART. During suppressive therapy, persisting HIV-1 contributes to low levels of viral replication and cell-to-cell spread driving the chronic immune cell activation and inflamming that ultimately sustains the HIV-1 reservoir in the body, together with homeostatic proliferation. However, evaluation of the intact provirus by IPDA showed a decrease of 3′ deletion/hypermutation in the provirus from PLWHc compared to PLWHART. Earlier studies have shown that 3′ deletion clones decline during suppressive therapy. These specific mutated proviruses may be under negative selection due to their capacity to stimulate the immune system. With a reduced proportion of provirus in PLWHc compared to PLWHART, it could be hypothesised that this lower negative selection is stronger in PLWHc, explaining the lower proportion of integrated HIV-1.

Monocytes produce pro-inflammatory cytokines where IM are efficient producers of IL6 and IL8 in response to microbial pathogens together with CM, whereas NCM produce TNF increased pro-inflammation. In response to viral elements, earlier studies have shown that integrated HIV-1 in total PBMCs compared to PLWHART, corroborating the principle proteomic analysis we hypothesise that the CD4+CCR6+ cells are more susceptible to apoptosis, while CD4+ T cells in PLWHc (CCR6−/CCR6+) exhibit decreased metabolic activation, indicative of a reduced activation state. Collectively, these lymphocytic cell populations may aid in facilitating the unique characteristics of PLWHc and contribute to chronic inflammation and HIV-1 persistence during suppressive therapy.

Methods

Patient material. The clinical cohort consisted of HIV-1+ individuals on suppressive therapy (PLWHc, n = 54), elite controllers (PLWHc, n = 14) collected from the InfCareHIV cohort at the Department of Infectious Diseases, Karolinska University Hospital, Sweden, and HIV-1 negative individuals (HC, n = 18). The cohort was age-matched and the median duration of treatment was 8 years (IQR: 6.75–19). Cohort characteristics can be viewed in Table 1 and treatment regimen for PLWHc in Supplementary Table 1. The cohort also consisted of longitudinal data within the PLWHART group (T1, n = 10 and T2, n = 10) (Supplementary Table 2). At the time of sampling, none of the study participants had any co-infections. Patient material consisted of plasma and PBMCs collected from whole blood using Ficoll-Paque (Cytiva).

This study was approved by the Regional Ethics Committee of Stockholm. Informed consent was given from all participants prior to inclusion, and data were anonymized and de-identified before analysis.

Flow cytometry and FACS. PBMCs were stained for cell surface markers for 20 min at room temperature (RT) using 5 µL/106 PBMCs of CD3 (OKT3, FITC, Biolegend #317366), CD4 (SK3, BV385, BD Bioscience #747745), CD8 (RPA-T8, BB701, BD Bioscience #747847), CD14 (G034E3, BV605, BD Bioscience #353436), and CD19 (HCD11, BD Bioscience #562456), CCR2 (G034E3, BV711, BD Bioscience #353436), and CD27 (BD, FITC, BD Bioscience #564256). Cells were washed two times using FACS buffer (PBS with 2% FBS and 2 mM EDTA) and fixed 15 min at RT using 2% paraformaldehyde. Results were acquired on BD FACS Symphony (BD Bioscience, USA) using laser and filter settings as indicated for BV395 (250/30 (505 LP), 710/50 (685 LP), 810/40 (770 LP), 488 nm blue (200 mW) for CD14, 530/30 (505 LP), 710/50 (685 LP), 561 nm Y/G (200 mW), 610/20 (600 LP) and 637 nm Red (140 mW), 670/30 and 780/60 (750 LP). Cell expression analysis and t-SNE were performed using Flowjo 10.6 (TreeStar Inc). Co-expression analysis was performed using the Boolean gating function and the visualization of complex data using Spiec57. Data from flow cytometry detection in PLWHc (n = 14) and HC (n = 8) samples were used from our earlier publication.

Cryopreserved PBMCs were used for fluorescent activated cell sorting (FACS) for subsequent proteomic analysis and DNA extraction. Cells were thawed and stained using anti-human CD3 (OKT3, FITC, Biolegend #317306), CD4 (SK3, PC5, Biolegend #344654), CD8 (RPA-T8, BV570, Biolegend #301038), CD14 (M5E2, BV510, Biolegend #301842), CD16 (3G8, BV786, BD Bioscience #563690), CCR6 (G034E3, BV711, Biolegend #353436), and CD27 (BD, FITC, BD Bioscience #564256) for 20 min at RT. Flow cytometry detection in PLWHc and PLWHART could be hypothesised that this lower negative selection is stronger in PLWHc, explaining the lower proportion of integrated HIV-1.

CD4+ T cell activation and inflammation were assessed by measuring the expression of TNF and IFNγ by intracellular staining. Samples of 10 µL supernatant for each sample were used for intracellular staining with anti-human TNF (eBioscience #606012), anti-human IFNγ (eBioscience #64-7466), and anti-human CD3 (OKT3, FITC, Biolegend #317306). Staining was performed using the QX200 Droplet Digital qPCR System (Bio-Rad) using 50 ng of genomic DNA for RPP30 quantification and 200 ng of genomic DNA for CCR6 quantification. RPP30 was used as an internal control with a constant value in all samples.

DNA extraction. Total DNA was extracted from whole PBMCs or collected cell populations by QIAamp Mini or QIAamp Micro DNA isolation kit (Qiagen), according to the manufacturers protocol.

HIV-1 DNA quantification. Patient PBMCs or sorted cells were used for quantification of total HIV-1 DNA by Internally Controlled qPCR (IC-qPCR) developed by Vicenti et al. In brief, total HIV-1 DNA was quantified using Takara Universal mastermix on the ABI 7500 and normalized to β-Actin levels, primer and probe details are described in Supplementary Table 3. For each sample, 200–500 ng were run per reaction in duplicates and data were normalised to background detection in HC.

Digital droplet PCR and intact proviral DNA assay (IPDA). Digital droplet PCR (ddPCR) was performed using the IQ200 Droplet Digital qPCR System (Bio-Rad). Samples consisting of 10 µL Supermix for proxies (no dUTPs) (Bio-Rad), 900 nM primers, 250 nM probe (labelled with either HEX or FAM) or 500 ng of genomic sample DNA and 50 ng of DNA for RPP30 quantification for shearing analysis and normalization, were emulsified with the IQ200 droplet generator. PCR reactions were performed with a C1000 thermal cycle (Bio-Rad) using the following thermal cycling protocol: 10 min at 95 °C for enzyme activation followed by 45 annealing/extension cycles of 30 s at 94 °C and 60 s at 57 °C and a final enzyme
deactivation step at 98 °C for 10 min. Subsequently, samples were read with the QX200 Droplet Reader (Bio-Rad) and analysed with the QuantaSoft software version 1.5 (Bio-Rad).

For the quantification of intact, 5′ deleted, and 3′ deleted/hypermutated proviruses, the Intact Proviral DNA Assay was performed as previously described19. Briefly, a first ddPCR was performed as described above with primer/ probe combinations for the packaging signal (Ψ), which frequently shows small mutations (CAM) for 30 min at room temperature. Proteins were digested with trypsin (sequencing grade from Promega) with a 1:20 ratio enzyme:protein overnight at 37 °C. Resulting peptides were cleaned-up using C-18 stage tips (ThermoFisher Scientific) according to manufacturer’s instructions and dried in a vacuum concentrator (Eppendorf). Cleaned peptides were labelled with TMT11plex™ tags (ThermoFisher Scientific) following manufacturer’s instructions. Briefly, peptides were resuspended in 100 mM triethylammonium bicarbonate and individual TMT tags were dissolved in dry acetonitrile (ACN). Peptides were labelled by adding the respective TMT tag solution, the mix was incubated for 1 h at room temperature, the reaction was quenched by adding 5% hydroxyamine and incubated for 15 min at RT. Labelled peptides were mixed in three different batches according to the scheme described in Supplementary Table 4, a pool of samples was used across the three batches to normalize and evaluate batch effect (TMT channel 131C).

Labelled peptides were fractionated using Pierce High pH Reversed-Phase Fractionation Kit columns (ThermoFisher Scientific) following manufacturer’s instructions. Briefly, columns were washed with 100% ACN and then conditioned with 0.1% trifluoroacetic acid (TFA). Peptides were dissolved in 0.1% TFA and loaded into the column by centrifugation at 3000 × g for 2 min. Columns were washed with 5% ACN in 0.1% triethanolamine (TEA), and peptides were eluted directly at 3000 × g by centrifugation at 3000 × g according to the ACN concentration in 0.1% TEA solutions: 10, 12.5, 15, 17.5, 20, 22.5, 25 and 50%. All fractions were dried down in a vacuum concentrator (Eppendorf) prior to LC-MS/MS analysis.

Fractionated peptides were analysed on an Ultimate 3000 UHPLC (ThermoFisher Scientific) hyphenated to an Orbitrap™ Lumos™ mass spectrometer (ThermoFisher Scientific). Peptides were loaded in an Acclaim PepMap trap column, 2 μm × 75 μm i.d. × 2 cm (Thermo Scientific) and separated in an EASY-Spray™ HPLC Column, 2 μm × 75 μm i.d. × 500 mm (Thermo Scientific) using a 120 min linear gradient. Data were acquired in data-dependent acquisition (DDA) mode, isolating the top 20 most intense precursors at 120,000 mass resolution in the mass range of m/z 375–1400, maximum injection time (IT) of 50 ms and dynamic exclusion of 30 s, precursors were isolated with 0.7 Th width. MS/MS scans were obtained using high collision energy of 34%, resolution of 45,000 and maximum IT of 86 ms. Proteins were searched against both SwissProt human and HIV-1 databases using the search engine Mascot Server v2.5.1 (MatrixScience Ltd) in Proteome Discoverer v2.5 (ThermoFisher Scientific) software environment allowing maximum two missed cleavages. Oxidation of methionine, deamination of asparagine and glutamine, TMT10plex modification of lysine and N-termini were set as variable modifications, while carboxymethylation of cysteine was used as fixed modification. The false discovery rate (FDR) was set to 1%.

Bioinformatics analysis. The data were normalized using quantile method from the R/Bioconductor package NormalizeDE v1.4.0. Missing data were imputed by employing the nearest-neighbour averaging method using impute.knn function from R package impute v1.60.0. Default setting was used for the data imputation. Technical variations in the data due to batch effect were removed using R function ComBat from the package sva v3.34. Differential expressions analysis was performed with R/Bioconductor package Limma v3.42.2. Gene-set enrichment analysis was performed using R/Bioconductor package piano v2.2.0. Gene-level t-statistics given by Limma, and hallmark gene set downloaded from MSigDB were used to find significantly enriched gene-sets. Gene-sets with Benjamini–Hochberg adjusted p-values <0.2 were considered as significantly enriched. Volcano and bubble plots were created using R package ggplot2 v3.3.2.

Statistics and reproducibility. Statistical analysis was performed using two-tailed Mann–Whitney U-test, and Wilcoxon ranked sum test or paired t-test for longitudinal data, based on the distribution of the data in Prism 8 (GraphPad Prism Software). Statistical significance was p < 0.05 for all analysis. Data were visualized using the package ggplot2 v3.3.2 in RStudio (v.1.3.1056). Correlation analysis was performed using Spearman’s correlation (p < 0.05) in RStudio (v.1.3.1056). All assays were performed in technical duplicates except for the flow cytometry evaluation that was performed in one replicate per sample.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD027749. Raw data for FACS and flow cytometry are available from the corresponding authors upon request. The source data underlying most graphs used in this manuscript are provided as a Supplementary data file (Supplementary Data 1, excel).

Received: 26 October 2021; Accepted: 24 March 2022; Published online: 13 April 2022.

References.
